Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 198

Results For "products"

2382 News Found

Evonik to build production plant for rhamnolipids in Slovakia
Biotech | January 14, 2022

Evonik to build production plant for rhamnolipids in Slovakia

The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years


Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’
Sustainability | January 13, 2022

Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’

The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People


Outlook for the Indian Pharma Industry remains stable for this year
Opinion | January 13, 2022

Outlook for the Indian Pharma Industry remains stable for this year

The stability is led by healthy demand in the domestic and emerging markets


Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
News | January 12, 2022

Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra

Ind-Ra expects revenue growth of over 12% in 2022.


Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets
News | January 11, 2022

Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets

CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Wacker and Biosyntia to develop production process for sustainable biotin
Biotech | January 11, 2022

Wacker and Biosyntia to develop production process for sustainable biotin

The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative


Prof. Jason Kovacic bags Agilent Thought Leader award
News | January 11, 2022

Prof. Jason Kovacic bags Agilent Thought Leader award

Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease


Molnupiravir best option to treat Covid-19 now: Experts
News | January 11, 2022

Molnupiravir best option to treat Covid-19 now: Experts

Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry